Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue
Inogen (NASDAQ: INGN) has announced preliminary, unaudited revenue results for Q4 and full-year 2024. The company estimates Q4 2024 revenue between $79.0-80.0 million, representing 4-5% year-over-year growth. Full-year 2024 revenue is estimated at $334.5-335.5 million, showing 6% growth and exceeding previous guidance of $329-331 million.
Performance was driven by strong double-digit growth in business-to-business revenue, while the company works on stabilizing direct-to-consumer revenue. Notable achievements include the launch of Rove 4 and FDA clearance for the SIMEOX 200 device, expanding global product offerings. The company will report official Q4 and full-year 2024 results after market close on February 25, 2025.
Inogen (NASDAQ: INGN) ha annunciato i risultati preliminari e non auditati delle entrate per il quarto trimestre e l'intero anno 2024. L'azienda stima un fatturato per il Q4 2024 tra $79,0-80,0 milioni, rappresentando una crescita del 4-5% rispetto all'anno precedente. Il fatturato dell'intero anno 2024 è stimato tra $334,5-335,5 milioni, con una crescita del 6% che supera le precedenti previsioni di $329-331 milioni.
Le performance sono state trainate da una forte crescita a due cifre nel fatturato B2B, mentre l'azienda si impegna a stabilizzare il fatturato diretto al consumatore. Tra i risultati notevoli si segnala il lancio del Rove 4 e l'approvazione FDA del dispositivo SIMEOX 200, ampliando l'offerta globale di prodotti. L'azienda rilascerà i risultati ufficiali del Q4 e dell'intero anno 2024 dopo la chiusura del mercato il 25 febbraio 2025.
Inogen (NASDAQ: INGN) ha anunciado resultados de ingresos preliminares y no auditados para el cuarto trimestre y el año completo 2024. La empresa estima que los ingresos del Q4 2024 estarán entre $79.0-80.0 millones, lo que representa un crecimiento del 4-5% en comparación con el año anterior. Se estima que los ingresos del año completo 2024 serán de $334.5-335.5 millones, mostrando un crecimiento del 6% y superando la guía anterior de $329-331 millones.
El rendimiento fue impulsado por un sólido crecimiento de dos dígitos en los ingresos de negocio a negocio, mientras la empresa trabaja en la estabilización de los ingresos directos al consumidor. Logros notables incluyen el lanzamiento del Rove 4 y la aprobación de la FDA para el dispositivo SIMEOX 200, ampliando la oferta global de productos. La empresa reportará resultados oficiales del Q4 y del año completo 2024 después del cierre del mercado el 25 de febrero de 2025.
Inogen (NASDAQ: INGN)은 2024년 4분기 및 전체 연도에 대한 잠정 비감사 매출 결과를 발표했습니다. 회사는 2024년 4분기 매출이 $79.0-80.0 백만 사이일 것으로 예상하며, 이는 전년 대비 4-5%의 성장률을 나타냅니다. 2024년 전체 연도 매출은 $334.5-335.5 백만으로 추정되며, 6% 성장세를 보이고 있으며, 이전 가이드라인인 $329-331 백만을 초과합니다.
성과는 B2B 매출에서 강력한 두 자릿수 성장이 주도했으며, 회사는 소비자 직접 판매 매출의 안정을 위해 노력하고 있습니다. 주목할 만한 성과로는 Rove 4의 출시와 SIMEOX 200 장치에 대한 FDA 승인이 있으며, 이는 글로벌 제품 제공을 확장하는 데 기여하고 있습니다. 회사는 2025년 2월 25일 장 마감 후 2024년 4분기 및 전체 연도 공식 결과를 보고할 예정입니다.
Inogen (NASDAQ: INGN) a annoncé des résultats préliminaires et non audités concernant les revenus pour le quatrième trimestre et l'année complète 2024. L'entreprise estime que les revenus du Q4 2024 se situeront entre $79,0-80,0 millions, représentant une croissance de 4-5% par rapport à l'année précédente. Les revenus de l'année 2024 sont estimés entre $334,5-335,5 millions, affichant une croissance de 6% et dépassant les prévisions précédentes de $329-331 millions.
La performance a été soutenue par une forte croissance à deux chiffres des revenus B2B, tandis que l'entreprise travaille à stabiliser les revenus directs aux consommateurs. Parmi les réalisations notables, on trouve le lancement du Rove 4 et l'approbation de la FDA pour l'appareil SIMEOX 200, élargissant ainsi l'offre de produits à l'échelle mondiale. L'entreprise publiera les résultats officiels du quatrième trimestre et de l'année 2024 après la clôture du marché le 25 février 2025.
Inogen (NASDAQ: INGN) hat vorläufige, ungeprüfte Umsatz Ergebnisse für das 4. Quartal und das Gesamtjahr 2024 bekannt gegeben. Das Unternehmen schätzt den Umsatz für das Q4 2024 zwischen $79,0-80,0 Millionen, was einem Wachstum von 4-5% im Vergleich zum Vorjahr entspricht. Der Umsatz für das Gesamtjahr 2024 wird auf $334,5-335,5 Millionen geschätzt und zeigt ein Wachstum von 6%, was die vorherige Schätzung von $329-331 Millionen übertrifft.
Die Leistung wurde durch starkes zweistelliges Wachstum im B2B-Umsatz unterstützt, während das Unternehmen daran arbeitet, den Umsatz im Direct-to-Consumer-Bereich zu stabilisieren. Zu den bemerkenswerten Erfolgen gehören die Einführung des Rove 4 und die FDA-Zulassung für das Gerät SIMEOX 200, wodurch das globale Produktangebot erweitert wird. Das Unternehmen wird die offiziellen Ergebnisse für das Q4 und das Gesamtjahr 2024 nach Handelsende am 25. Februar 2025 veröffentlichen.
- Q4 2024 revenue growth of 4-5% year-over-year
- Full-year 2024 revenue exceeded guidance, growing 6%
- Strong double-digit growth in B2B revenue
- FDA clearance obtained for SIMEOX 200 device
- Successfully launched new product Rove 4
- Direct-to-consumer revenue still requires stabilization
Insights
The preliminary Q4 and FY2024 revenue figures from Inogen reveal a notable turnaround story. The projected Q4 revenue of
Breaking down the numbers: The
The dual focus on revenue growth and profitability enhancement through cost management is strategically sound. Product diversification with Rove 4 and SIMEOX 200 strengthens the company's competitive position in the respiratory care market, potentially creating new revenue streams and reducing dependency on existing product lines.
The FDA clearance of SIMEOX 200 and launch of Rove 4 represent significant product portfolio expansion in the respiratory care space. These developments are particularly noteworthy as they address different segments of the respiratory care market - Rove 4 targeting the portable oxygen concentrator segment while SIMEOX 200 diversifies into airway clearance therapy.
The respiratory device market is experiencing increased demand due to aging populations and rising chronic respiratory conditions. Inogen's strategic positioning with these new products, combined with their established presence in home respiratory care, creates multiple growth vectors. The B2B channel's strong performance suggests growing acceptance among healthcare providers and institutional buyers, potentially indicating improved product positioning and competitive advantages in clinical settings.
The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2024 to be in the range of
The Company estimates preliminary, unaudited total revenue for the full year 2024 to be in the range of
“2024 was a very successful year for Inogen. We drove a return to revenue growth, improved profitability and disciplined cost management. Achievements in the quarter included the launch of Rove 4 and FDA clearance for our SIMEOX 200 device which diversifies our global product offerings, all while continuing to extend our reach and aiming to improve outcomes for patients,” said Kevin Smith, President and Chief Executive Officer of Inogen. “I am confident in our team’s ability to continue delivering on our commitments and providing leading devices for patients with respiratory diseases in 2025 and beyond.”
The Company will report its official fourth quarter and full year 2024 financial results after the market closes on Tuesday, February 25, 2025. On the same day, Inogen management will host a conference call beginning at 2:00 pm PT / 5:00 pm ET.
Individuals interested in listening to the conference call may do so by dialing:
US domestic callers (877) 841-3961
Non-US callers (201) 689-8589
Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. This webcast will also be archived on the website for 6 months.
A replay of the call will be available approximately three hours after the live webcast ends and will be accessible through March 4, 2025. To access the replay, dial (877) 660-6853 or (201) 612-7415 and reference Conference ID: 13750589.
About Inogen
Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease.
For more information, please visit www.inogen.com.
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that are not historical facts, including, but not limited to, statements regarding Inogen’s future business plans, market opportunities, financial outlook, growth strategies, and anticipated operational results, are forward-looking statements. Words such as “aims,” “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks and uncertainties relating to market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations; unanticipated increases in costs or expenses; risks associated with international operations; and the possibility that Inogen will not realize anticipated revenue from recent or future technology acquisitions or that expenses and costs related thereto will exceed Inogen’s expectations. For a detailed discussion of these and other risks that could impact Inogen’s operations and financial performance, please refer to the “Risk Factors” section of its Annual Report on Form 10-K for the period ended December 31, 2023, its Quarterly Report on Form 10-Q for the calendar quarter ended March 31, 2024 and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113477433/en/
Source: Inogen, Inc.
FAQ
What is Inogen's (INGN) estimated revenue for Q4 2024?
Did Inogen (INGN) exceed its 2024 revenue guidance?
What new products did Inogen (INGN) launch in 2024?
When will Inogen (INGN) report its official Q4 and full-year 2024 results?
What drove Inogen's (INGN) revenue growth in 2024?
